Pfizer faces more Bosulif bother as NICE issues final no
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has joined the growing swell of European HTAs rejecting Pfizer's chronic myeloid leukemia (CML) drug Bosulif (bosutinib).